Clinical Trials
12 trialsNCT05248022 2024-01-09
Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure
The Central Hospital of Lishui City
Phase NA Unknown
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT05638425 2022-12-06
Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases
Xiangya Hospital of Central South University
Unknown
NCT05603013 2022-11-02
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05520853 2022-08-30
SBRT Combined With PD-1 Inhibitor and Thoracic Hyperthermia for Advanced NSCLC
First People's Hospital of Hangzhou
Phase 2 Unknown
NCT05273814 2022-07-13
Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 1 Unknown
NCT04941417 2021-06-28
Neoadjuvant Immunotherapy With Chemotherapy for Stage I-IIIB Non-Small Cell Lung Cancer Patients
Peking Union Medical College
Phase 2 Unknown
NCT04629027 2021-02-24
Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLC
Peking University Cancer Hospital & Institute
Unknown
NCT04613804 2020-11-03
Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy
Fujian Cancer Hospital
Phase 2 Unknown
NCT03987867 2020-07-07
Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC
Tianjin Medical University Cancer Institute and Hospital
Phase 1 Unknown
NCT04115410 2020-05-28
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
Unknown
NCT04355806 2020-04-21
Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors
Shanghai Pulmonary Hospital, Shanghai, China
Unknown